Radiopharmaceutical Treatment of Advanced Kidney Cancer

Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy. Unfortunately, treatment options at this stage of the disease are limited. The existing treatments' ability to work against cancer has not been fully looked into. Rationale The goal of this study is to examine if a new drug treatment called 177Lutetium-PSMA-617, hereafter referred as 177Lu-PSMA-617, which holds the active ingredient 177Lutetium-PSMA and has been used as a standard treatment for advan

Trial Details

NCT ID
NCT06783348
Phase
PHASE2
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • 177Lu-PSMA-617
Locations (sample)
  • Caen, France|49.18585,-0.35912
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • PRE-SCREENING
  • Histologically proven ccRCC. Sarcomatoid component is allowed.
  • Adult patients ≥18 years old.
  • Has progressed on or after ≥1-line prior systemic therapy approved in the metastatic setting. Prior treatment must include an anti-programmed death…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →